30 closest matches · ranked by relevance
Nasopharyngeal Nonkeratinizing Carcinoma · Recurrent Nasopharynx Carcinoma · Stage III Nasopharyngeal Carcinoma AJCC v7
Primary: Confirmed Response Rate (Complete Response or Partial Response) Based on RECIST Version 1.1 — 20.5 percentage of patients with a response
Head and Neck Cancer
Primary: Survival Rate of Patients — 33 months
Nasal Polyps · Gastroesophageal Reflux
Primary: Presence of Reflux in Patients With Polyposis — 15 participants
Nasopharyngeal Carcinoma
Primary: Number of Participants With Acute Toxicity — 23 Participants
Nasopharyngeal Carcinoma
Primary: Rate of Completion of All Adjuvant Immunotherapy — 100 percentage of participants
Paranasal Sinus Cancer · Nasal Cavity Tumor · Nasal Cavity Adenocarcinoma
Primary: Local Control Assessment of Unresectable Paranasal Sinus and Nasal Cavity Tumors
Recurrent Lymphoepithelioma of the Nasopharynx · Recurrent Squamous Cell Carcinoma of the Nasopharynx · Stage IV Lymphoepithelioma of the Nasopharynx
Primary: Clinical Benefit Rate — 54.5 percentage of participants
Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Primary: Percentage of Patients With a Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment During the…
Stage II Lymphoepithelioma of the Nasopharynx · Stage II Squamous Cell Carcinoma of the Nasopharynx · Stage III Lymphoepithelioma of the Nasopharynx
Primary: Number of Participants With Progression-free Survival (PFS) at 2 Years After Chemo-radiotherapy — 18; 4 Participants
Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7 · Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Primary: Two Year Event-free Survival (EFS) — 0.87 Estimated probability
Head and Neck Cancer · Oral Complications of Radiation Therapy · Radiation Toxicity
Primary: Protocol Compliance of Intensity-modulated Radiotherapy Treatment Delivered — 9 participants
Nasopharyngeal Carcinoma
Primary: Best Overall Response Rate (ORR) — 0.0 percentage of participants
Nasopharyngeal Carcinoma
Primary: Positive Nasopharynx Biopsy Results Detected by NBI System in Those Post-radiotherapy 8th Week NPC Patient — 14; 1; 20; 1 participants
Nasopharyngeal Neoplasms
Primary: Percentage of Participants Who Achieved a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Based on an Independent…
Nasopharyngeal Carcinoma
Primary: Progression-free Survival (PFS) as Per RECIST v 1.1 Using Central Assessment - Number of Participants With Progression or Death — 62; 32; 3; 1 Participants
Nasopharyngeal Carcinoma
Primary: 3 Month Loco-regional Control After Cetuximab With Concurrent Chemoradiotherapy — 100 participants with loco-regional control
Nasal Polyps
Primary: Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 52 — 0.0; -1.0 Scores on a scale — p=<0.001
Head and Neck Cancer · Oral Cancer
Primary: Number of Participant Exams in Which Providers Reported the FNS (Flexible Nasopharyngoscope) is Easy to Use — 0; 9; 33; 6 Participant exams
Dysphagia
Primary: The Change From Baseline and Cut Point VFSS in Velocity of Displacement of Hyoid Bone at 1 to 3 Months — 0.8; -0.4 cm/s
Nasopharyngeal Carcinoma
Primary: Overall Survival (OS) of Subjects With Advanced Nasopharyngeal Carcinoma. — 25; 24.9 Months — p=0.1942
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Squamous Cell Carcinoma of the Head and Neck · Nasopharyngeal Carcinoma · Salivary Gland Cancer
Primary: Local Control Rate — 1; 5 Participants
Recurrent or Metastatic NPC
Primary: IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1 — 8.2; 21.4 months
Nasopharyngeal Cancer
Primary: Comparing the Level of Urinary N-telopeptide (uNTx) in the Two Arms . — 75; 94; 29; 88 nM /mM — p=0.370
Recurrent Head and Neck Cancer
Primary: Safety Measures (Adverse Events and Laboratory Parameters) With Repeat Cycles of Treatment. — 5; 0; 8; 8 Participants
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Nasal Polyps
Primary: Number of Participants With a Reduced Need for Surgery at Week 25 — 16; 5; 33; 46 Participants — p=0.003
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Nasopharyngeal Neoplasms · Carcinoma
Primary: Number of Participants With Complete Response (CR) — 1; 0 participants — p=1.0000
Nasal Polyps
Primary: Change From Baseline in Bilateral Endoscopic Nasal Polyp Score (NPS) at Week 16 — 5.67; 5.87; 5.39; 3.97 score on a scale — p=0.0009